Biogen Negotiating Medicare Volume Deal That Might Increase Spending

By John Wilkerson / June 23, 2021 at 5:43 PM
Biogen is open to lowering the price of its Alzheimer’s drug Aduhelm if it’s more widely prescribed than expected, and the company is negotiating Medicare volume-based pricing agreements, Biogen said Wednesday (June 23) after weeks of backlash over its average $56,000 annual price. Volume-based agreements lower prices as prescriptions rise, but they also encourage more use, which can cause higher overall spending. “We have determined the launch price of ADUHELM based on our belief in the impact of treatment as...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.